#Expert Research: Can CBD effectively impede growth of heterotopic lung cancer?

Lung cancer is the most chronic form of cancer and the leading cause of cancer mortality in the world, according to studies by the American Lung Association.

Despite recent advances in medical oncology, metastatic lung cancer remains incurable; however, a new discovery by Augusta University researchers has brought new hope to tackling the illness.

That discovery, which stems from a joint preclinic study conducted by scientists from the Dental College of Georgia and the Medical College of Georgia at Augusta University and Medicinal Cannabis of Georgia, LLC, was published in the May 2023 issue of Human Cell.

The study was led by Babak Baban, PhD, associate dean of research, immunologist and professor at DCG and one of the founders of Medicinal Cannabis of Georgia, an Augusta-based biomedical research and developmental company.

The study revealed for the first time that inhalant cannabidiol, commonly referred to as CBD, can effectively impede growth of heterotopic lung cancer.

“The central core of our research has been studying inflammatory diseases and for that we picked two different directions: one is centered around chronic inflammation in our system and the other is neurologic diseases such as dementia. Because of their impressive anti-inflammation effects, CBD, CBC and other cannabinoids have attracted our attention,” Baban said.

“We have had some exciting findings before, and based on those, we built a new model of lung cancer. This is the first time the effect of the CBD has been assessed in inhalant format using an inhaler. This makes it more translatable into humans and more accurate,” he said.

“Obviously, we are just as excited about our discoveries on mechanisms by which CBD worked. They help advance our understanding of the pathophysiology of lung cancer. We have seen some effects on plasticity and cancer stem cells, which appear to be crucial for tumors to regenerate and renew themselves.”

Unlike most anti-angiogenesis drugs, inhalant CBD at the experimental dosage did not show any detectable side effects or toxicity. The findings support the notion that inhalant CBD has enough beneficial effects as a viable complementary modality to be included in combination with current standard treatments for lung cancer.

Additionally, inhalant CBD delivered using a precisely metered dose is non-invasive, and has high translational value, warranting further research through clinical trials for lung cancer and possibly some other malignancies.

“The cannabis plant has over 113 cannabinoids, two of which are very famous: THC and cannabidiol, or CBD. We have conducted extensive research on medicinal cannabis since 2014, but cannabis has been utilized for medicinal purposes for over 1,000 years,” Baban said. “It is not until recently we have started understanding a little better mechanisms how cannabidiols like CBD work.”

Babak Baban is a professor, immunologist and associate dean for research at the Dental College of Georgia at Augusta University where he has served for 13 of his 20 years as a translational and clinical immunologist.

Babak is available to speak to media about this important topic - simply click on his icon now to arrange a time to speak today.